Skip to main content

Braving the IPO Drought

Despite nervous investors and a volatile market, a courageous few biotechnology companies are taking their chances on Wall Street.

Written byMegan Scudellari
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00

GOING PUBLIC: Gajus Worthington, founder and CEO of Fluidigm, and the rest of the California-based biotech team in Times Square on February, 10, 2011, the day the company went public, raising $75 million. NASDAQ STOCK EXCHANGE

In 2000, Wall Street fell in love with biotechnology. Biotech stocks flew off the shelves as investors clamored to get cozy with companies working on tantalizing new concepts like “genomics” and “gene-based therapies.” In total that year, US biotechs completed 63 initial public offerings (IPOs), raising $5.4 billion in funding.

But that love affair has long since soured. Gajus Worthington remembers the falling-out vividly. “It was a nightmare,” recalls Worthington, CEO of Fluidigm, a California-based biotech tools company. Fluidigm had plans to “go public”—issue shares of stock in the open market for the first time—in late September 2008. But on Sunday, September 14, mega-investment banks Merrill Lynch and Lehman Brothers collapsed and the stock market tanked, taking Fluidigm’s plans with it. “Investors were depressed, catatonic, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

Published In

Related Topics

November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo
Optimizing Critical Steps in T-Cell Engineering

Optimizing Critical Steps in T-Cell Engineering

Fujifilm

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen